Fauna Bio Announces Target Designation Milestone in Obesity Discovery Collaboration
Fauna Bio, a biotechnology company pioneering the use of extreme mammal biology and comparative genomics to discover novel therapeutic targets, today announced the designation of a target under its strategic obesity discovery collaboration with Eli Lilly and Company (Lilly), initiated in December, 2023.
Fauna Bio Launches Fauna Brain™ AI Platform to Accelerate Drug Discovery Inspired by Nature’s Most Resilient Species
Fauna Bio, a biotechnology company harnessing animal genomics to improve human health, today announced the launch of Fauna Brain™, a proprietary AI platform designed to accelerate target discovery and streamline early-stage R&D. The platform represents a major evolution of Fauna Bio’s Convergence™ discovery engine and is already delivering results in both internal programs and external pharma partnerships.
Fauna Bio Announces First Candidate Nomination of Faun1083 for the Treatment of Heart Failure
Fauna Bio, a biotechnology company improving human health by leveraging animal genomics, today announced Faun1083 as its first development candidate. Discovered through Fauna Bio’s proprietary Convergence™ drug discovery platform, Faun1083 is a potential first-in-class therapeutic targeting heart failure with preserved ejection fraction (HFpEF), a disease with currently limited treatment options.
Fauna Bio Researcher Awarded NASA Early-Stage Grant to Study Hibernation in Space
Fauna Bio, a biotechnology company that leverages animal genomics to improve human health, announces Senior Research Physiologist Ryan Sprenger, Ph.D., has been awarded a NASA Innovative Advanced Concepts (NIAC) grant.
